Bio-Rad Laboratories (BIO) Stock Forecast, Price & News

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Bio-Rad Laboratories in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" BIO shares.
View BIO analyst ratings or view top-rated stocks.

3 Wall Street analysts have issued 12-month price objectives for Bio-Rad Laboratories' shares. Their BIO share price forecasts range from $579.00 to $700.00. On average, they predict the company's stock price to reach $653.00 in the next twelve months. This suggests a possible upside of 72.3% from the stock's current price.
View analysts price targets for BIO or view top-rated stocks among Wall Street analysts.

Bio-Rad Laboratories' stock was trading at $420.49 at the beginning of the year. Since then, BIO stock has decreased by 9.9% and is now trading at $379.00.
View the best growth stocks for 2023 here.

Bio-Rad Laboratories saw a increase in short interest in May. As of May 15th, there was short interest totaling 291,200 shares, an increase of 23.2% from the April 30th total of 236,400 shares. Based on an average daily volume of 191,400 shares, the days-to-cover ratio is currently 1.5 days. Approximately 1.4% of the company's stock are sold short.
View Bio-Rad Laboratories' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, July 27th 2023.
View our BIO earnings forecast.

Bio-Rad Laboratories, Inc. (NYSE:BIO) announced its earnings results on Thursday, May, 4th. The medical research company reported $3.34 EPS for the quarter, topping the consensus estimate of $3.24 by $0.10. The medical research company earned $676.80 million during the quarter, compared to analysts' expectations of $689.28 million. Bio-Rad Laboratories had a positive trailing twelve-month return on equity of 4.10% and a negative net margin of 7.01%. The business's revenue was down 3.3% on a year-over-year basis. During the same period in the previous year, the company posted $4.94 EPS.
Read the conference call transcript.

ETFs with the largest weight of Bio-Rad Laboratories (NYSE:BIO) stock in their portfolio include Putnam BioRevolution ETF (SYNB), Harbor Health Care ETF (MEDI), ETFMG Treatments Testing and Advancements ETF (GERM), Principal Healthcare Innovators ETF (BTEC), Formidable Fortress ETF (KONG), Putnam Sustainable Future ETF (PFUT), First Trust Indxx Medical Devices ETF (MDEV) and Invesco S&P 500 Equal Weight Health Care ETF (RYH).

Bio-Rad Laboratories issued an update on its FY 2023 earnings guidance on Thursday, May, 4th. The company provided EPS guidance of for the period. The company issued revenue guidance of $2.93 billion-$2.93 billion, compared to the consensus revenue estimate of $2.97 billion.

325 employees have rated Bio-Rad Laboratories Chief Executive Officer Norman Schwartz on Glassdoor.com. Norman Schwartz has an approval rating of 84% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Bio-Rad Laboratories investors own include BioMarin Pharmaceutical (BMRN), Incyte (INCY), Puma Biotechnology (PBYI), AbbVie (ABBV), NVIDIA (NVDA), Broadcom (AVGO), Johnson & Johnson (JNJ), Advanced Micro Devices (AMD), Alibaba Group (BABA) and Intel (INTC).

Bio-Rad Laboratories trades on the New York Stock Exchange (NYSE) under the ticker symbol "BIO."

Bio-Rad Laboratories' stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (5.40%), Veritas Asset Management LLP (3.89%), State Street Corp (3.11%), Brown Advisory Inc. (2.86%), Bank of America Corp DE (1.55%) and Geode Capital Management LLC (1.50%). Insiders that own company stock include Ajit Ramalingam, Annette Tumolo, Giovanni Magni, Ilan Daskal, Michael Crowley, Timothy S Ernst and Timothy S Ernst.
View institutional ownership trends.

Shares of BIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of BIO stock can currently be purchased for approximately $379.00.

Bio-Rad Laboratories (NYSE:BIO) has a market capitalization of $11.22 billion and generates $2.78 billion in revenue each year. The medical research company earns $-3,627,530,000.00 in net income (profit) each year or ($6.54) on an earnings per share basis.

The company employs 8,200 workers across the globe.

Bio-Rad Laboratories' mailing address is 1000 ALFRED NOBEL DRIVE, HERCULES CA, 94547. The official website for the company is www.bio-rad.com. The medical research company can be reached via phone at (510) 724-7000, via email at investor_relations@bio-rad.com, or via fax at 510-741-5817.